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Donor leukocyte infusion (DLI) can induce potent graft-versus-leukemia (GVL) activity inpatientswith relapsed
hematologic malignancies after allogeneic hematopoietic stem cell transplantation (HSCT). Unfortunately,
except in patients with chronic-phase chronic myelogenous leukemia, responses to DLI have been disap-
pointing. GVL induction is likely to be most effective in the setting of minimal residual disease. Prevention of
relapse through the provision of prophylactic DLI to high-risk patients may improve the outcome of allogeneic
HSCT. We previously reported that ex vivo costimulated T cell infusion of activated DLI (aDLI) as treatment for
relapse is safe and has potent GVL effects. We hypothesized that prophylactic aDLI can be given safely and
prevent relapse in high-risk patients after allogeneic HSCT. Eighteenpatientswith acutemyeolgenous leukemia
(n ¼ 14), acute lymphoblastic leukemia (n ¼ 3), or myelodysplastic syndrome (n ¼ 1) underwent allogeneic
HSCTafter a reduced-intensity conditioning (RIC) regimenwith alemtuzumab,ﬂudarabine, and busulfan. Graft-
versus-host-disease (GVHD) prophylaxis consisted of tacrolimus and methotrexate with a planned early and
rapid taper of tacrolimus. Patients without GVHD, off immune suppression, and in remission received aDLI at
a dose of 1  107 CD3þ cells/kg (aDLI 1) at day þ120, followed by a second infusion of 1  108 CD3 cells/kg
(aDLI 2) at day þ180. At a median follow-up of 58 months, 5 of the 18 patients (28%) were alive, and 4 patients
were in remission. Eleven patients (65%) relapsed, at a median time of 191 days. Twelve of the 18 patients
received at least one aDLI, and 6 of these 12 patients also received aDLI 2. Six patients did not receive any aDLI
owing to early relapse (n ¼ 2), protocol ineligibility (n ¼ 1), or GVHD (n ¼ 3). Only 2 of the 12 patients who
received aDLI 1 developed GVHD. Two out of the 12 patients remain in remission at the time of this report.
Disease recurrence was the cause of death in 10 of the 13 patients (77%) who died. Our data indicate that
prophylactic ex vivo costimulated CD3/CD28 DLI is safe, feasible, and not associated with signiﬁcant GVHD.
Relapse remains the major cause of treatment failure after RIC HSCT even with rapid withdrawal of immune
suppression and the use of prophylactic aDLI, and better strategies to prevent relapse are needed.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Successful allogeneic hematopoietic stem cell trans-
plantation (HSCT) depends on both the conditioning therapy
and, particularly in the setting of reduced-intensity condi-
tioning (RIC) HSCT, on the graft-versus-leukemia (GVL)
activity, independent of conditioning. Relapse is now the
major cause of treatment failure after allogeneic HSCT.
Although RIC results in lower morbidity and mortality from
the conditioning regimen compared with myeloablative
conditioning, it is associated with higher relapse rates [1,2].
Relapse rates may be particularly high when Tcelledepleting
antibodies are included in the conditioning regimen [3].
One of the critical challenges in managing relapse after
allogeneic HSCT is to augment and optimize the GVL effect
without increasing the risk for GVHD. Currently, the only
approaches anticipated to result in long-term beneﬁt for
patients with relapsed leukemia are DLI and second HSCT.edgments on page 1100.
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13.04.021However, outcomes from DLI after HSCT have been disap-
pointing in patients with relapsed acute myelogenous
leukemia (AML) and acute lymphoblastic leukemia (ALL).
Although ALL has a well-described GVL effect [4], the use of
DLI in relapsed ALL is associated with a dismal overall
survival rate of 0%-13% [5,6]. Even when DLI is effective in
fostering a GVL effect, it may be difﬁcult to separate GVL from
GVHD, given that most patients who respond to DLI suffer
from GVHD [5,7,8].
DLI for relapsed disease may have limited efﬁcacy, owing
to multiple factors resulting in ineffective donor T cell acti-
vation. In relapsed ALL, induction of T cell anergy may
contribute to the failure of DLI [9]. In addition, donor CD8þ T
cells develop replicative senescence as early as 2 months
after HSCT, which may have implications for a poor response
to DLI [10]. Inadequate expression of costimulatory adhesion
molecules may also contribute to failure of DLI.
We hypothesized that ex vivo activation and expansion of
donor T cells through CD3/CD28 costimulation could bypass
many of the mechanisms limiting GVL activity after DLI. We
have used activated DLI (aDLI) to treat patients with relapsed
leukemia after allogeneic HSCT, and have shown that thisTransplantation.
Figure 1. Patient treatment protocol. Schematic of patient treatment from pre-HSCT conditioning to aDLI 2 administration.
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results in signiﬁcant remission rates for small numbers of
patients with AML and ALL [11]. We hypothesized that to be
most effective, GVL induction should be provided at the time
of minimal residual disease, and we studied the safety and
feasibility of aDLI for restoring GVL activity and preventing
relapse after RIC allogeneic HSCT using in vivo T cell deple-
tionwith alemtuzumab in high-risk adult patients with AML,
ALL, and MDS.
PATIENTS AND METHODS
The study protocol and consent forms were approved by the Institu-
tional Review Boards of the University of Pennsylvania and the National
MarrowDonor Program (NMDP). The study is registered at ClinicalTrials.gov
(NCT00374933). Written informed consent was obtained from each
participating recipient and donor. The protocol design is shown in Figure 1.
Conditioning
All patients received the following conditioning regimen: alemtuzumab
10 mg s.c. on day -9 and 30 mg on days -8, -7, and -6 (total dose, 100 mg);
i.v. ﬂudarabine 30 mg/m2 daily from day -6 through day -3 (total dose,
120 mg/m2); and i.v. busulfan 0.8 mg/kg every 6 hours for a total of 8 doses
from day -4 through day -3 (total dose, 6.4 mg/kg). All time points are listed
in reference to HSCT on day 0.
GVHD Prophylaxis
All patients received i.v. tacrolimus starting on day -3 and i.v. metho-
trexate, 15 mg/m2 on day þ1 and 10 mg/m2 on days þ3, þ6, and þ11.
Intravenous tacrolimus was converted to oral dosing when the patient could
tolerate oral medications, and a target range of 5-15 mg/mL was maintained
until day þ40, when tapering began for planned discontinuation of tacro-
limus by day þ110 (before infusion of aDLI). Patients were assessed at least
weekly to ensure that no GVHD had developed before administration of
aDLI. Acute GVHD was scored using the International Bone Marrow Trans-
plant Registry severity index [12], and chronic GVHD was scored using
National Institutes of Health consensus guidelines [13].
Supportive care was provided in accordance with institutional guide-
lines, including voriconazole 200 mg twice daily, acyclovir 800 mg twice
daily, and Bactrim DS 3 times weekly (after engraftment). Cytokines were
not used to facilitate neutrophil recovery.
Peripheral Blood Stem Cell Collection/Infusion
Sibling donors were mobilized with 10 mg/kg granulocyte colony-
stimulating factor for 4 days and underwent large-volume leukapheresis
on the ﬁfth day in accordance with institutional guidelines to coincide with
day 0 of recipient conditioning. Peripheral blood stem cells (PBSCs) from
unrelated donors were collected under the auspices of the NMDP and
according to individual donor center policies. Fresh PBSCs were infused on
day 0 following institutional guidelines.
Activated DLI
Preparation of aDLI
Approximately 10 days before the ﬁrst planned aDLI (day þ120), donors
underwent large-volume leukapheresis (no cytokine priming) used for
costimulated aDLI as described previously [14,15]. In brief, after ex vivoculture with CD3/CD28-coated magnetic beads for 10 days, the beads were
washed and concentrated with a Baxter Fenwal cell harvester. Quality
control ensured the safety of infused cells by testing for viability, removing
residual beads, and documenting lack of contamination via bacterial and
fungal cultures, Gram stain, and endotoxin assays.
After collection, the product for the second infusion was cryopreserved
in 10% DMSO until the second infusion date. The ﬁrst infusion was infused
“fresh” after expansion/activation, and the second dose was a cryopreserved
aliquot from the original product.
Rationale for aDLI dose
The doses of 1 107 CD3þ cells/kg for the ﬁrst aDLI infusion and 1 108
CD3þ cells/kg for the second infusion were selected based on the results of
our previous phase I trial [11]. In that study, aDLI was given for relapsed
disease, and the maximum tolerated dose was not achieved at doses up to
1 108 CD3þ cells/kg. The phase I trial also conﬁrmed that the planned cell
doses for this trial can be obtained and expanded from a single leukaphe-
resis product. Because the patients in the present study were in remission at
the time of aDLI, we chose a lower initial cell dose, followed by a dose-
escalation strategy.
Rationale for timing of prophylactic aDLI
Because it was deemed biologically relevant to defer prophylactic aDLI
until recipients had successfully completed tapering of post-transplantation
immunosuppression, the timing of the infusions was tied to the pace at
which each patient completed this process. The GVHD prophylaxis and
subsequent taper was designed to have patients off immunosuppression by
day þ100 (once they had recovered from acute toxicities of transplantation)
and to allow for aDLI by day þ120.
To receive the initial planned infusion of aDLI at approximately
dayþ120 and the second infusion at dayþ180, the following conditions had
to be met: (1) evidence of>10% donor chimerism in peripheral blood; (2) no
evidence of hematologic relapse; (3) no evidence of GVHD; and (4)
successful taper of all immunosuppression before infusion.
Chimerism Analysis
Whole-blood chimerism analysis from peripheral blood was performed
at day þ30, day þ60, day þ90, before infusion of aDLI, day þ240, and
day þ365 by short tandem repeat analysis [16]. Bone marrow samples were
assessed at day þ100.
Immunology Studies
Samples for functional analysis were obtained at the following time
points: before conditioning, day þ60, day þ90, before aDLI 1 (wday þ120),
before aDLI 2 (wday þ170), and day þ365. Target sample volume was set at
40-60 mL per time point. Samples were processed and mononuclear cells
were isolated and cryopreserved in accordance with University of Penn-
sylvania Human Immunology Core Lab protocols. Batched samples were
thawed and effector cell function was analyzed using dilution of carboxy-
ﬂuorescein succinimidyl ester to measure proliferation, ELISpot to deﬁne
IFN-g secretion, and CD107a expression to measure degranulation/cyto-
toxicity. Assays were performed under the supervision of Human Immu-
nology Core Lab staff.
Statistical Analyses
Patient data were recorded throughout the treatment course and eval-
uated using median values. Differences in absolute lymphocyte count (ALC)
between patients receiving at least 1 aDLI and patients not receiving DLI
Table 1
Patient characteristics
Characteristic Value
Total number of patients 18
Patient age, yr, median (range) 60.5 (54-68)
CD 34þ cell dose infused (per kg),
median (range)
5.0  106 (1.2  106-1.54  107)
Sex, male/female, n 12/6
Disease and status, n (%)
ALL 3 (17)
CR1 1 (6)
CR2 2 (11)
AML 14 (78)
CR1 from MDS 2 (11)
CR1 8 (44)
CR2 4 (22)
MDS 1 (6)
<5% blasts 1 (6)
Donor type, n (%)
Unrelated 8 (44)
Sibling 10 (56)
CMV serostatus, recipient/donor,
n (%)
Negative/negative 5 (27)
Negative/positive 5 (27)
Positive/negative 4 (22)
Positive/positive 4 (22)
Mismatch 9 (50)
ABO compatability
Match 15 (83)
Mismatch 3 (17)
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curves were created to evaluate relapse-free survival and overall survival.
For correlative analysis of GVHD, factors were analyzed as nominal variables
using the Kendall T test. Statistical signiﬁcance was indicated by a P value
.05. All statistical analyses were conducted with JMP 8 software (SAS
Institute, Cary, NC).RESULTS
Patient Characteristics
Patient characteristics are summarized in Table 1. The
median patient age was 61 years. Patients received gran-
ulocyte colony-stimulating factoremobilized PBSCs from
apheresis products from a matched sibling donor (n ¼ 10) or
amatched unrelated donor (n¼ 8). All patients were deemed
at high risk for disease-related mortality without HSCT
owing to age, karyotype, or previous relapsed disease. One
patient with ALL in ﬁrst complete remission (CR1) was
excluded from receiving aDLI after RIC HSCT because of an
HLA allele mismatch.Feasibility of Prophylactic Ex Vivo aDLI
An adequate number of activated T cells were generated
froma single apheresis session for both planned doses of aDLI
(1.1108 CD3þ cells/kg) in all but 1 recipient (Figure 2). Eight
donors were recruited from the NMDP, and all were available
for subsequent DLI donation after initial stem cell collection.
One product from an unrelated donor expanded poorly,
allowing for aDLI 1 at 100% of the planned dose and aDLI 2 at
a dose lower than planned (1.87 106 CD3/kg). Twelve of the
18 patients (67%) received aDLI 1 of fresh ex vivo costimu-
lated donor cells at a dose of 1  107 CD3/kg, at median
day þ125 (range, day þ119 to day þ172), demonstrating the
feasibility of pursuing prophylactic aDLI in the majority of
patients using an accelerated tacrolimus taper with a short
course of methotrexate and including alemtuzumab in the
conditioning regimen. Owing to issues of donor availability,
some patients received aDLI later than dayþ120. Six patientsdid not receive the ﬁrst planned infusion because of early
relapse (n¼ 2), GVHD (n¼ 3), or protocol ineligibility (n¼ 1).
No infusion-related toxicity was observed with aDLI 1. One
patient developed transient uveitis on day þ146 after HSCT
(dayþ27 after aDLI 1). Although this casewas not classiﬁed as
classic acute or chronic GVHD, the infection precluded her
from receiving aDLI 2.
Of the 12 patients who received aDLI 1, 6 (50%) went on to
receive the second dose-escalated planned infusion at
median dayþ184 (range, dayþ179 to dayþ237), 5 of the 6 at
an escalated dose of 1  108 CD3/kg and the sixth at
a reduced dose of 1.87  106 CD3/kg owing to poor ex vivo
expansion. The 6 patients that were excluded from aDLI 2
after receiving aDLI 1 were ineligible owing to GVHD in 2
cases (at days þ161 and þ186), uveitis in 1 case (day þ146),
and relapsed disease in 3 cases. No infusion-related toxicities
were associated with aDLI 2.
Engraftment
Myeloid and platelet engraftment after RIC HSCT is
summarized in Table 2. The median time to ANC >500/mL
post-HSCT was 18 days (range 0 to 27 days), and the median
time to platelet independence post-HSCTwas 12 days (range,
0 to 118 days). No patient experienced primary or secondary
graft failure.
The ALC improved steadily over time, with a median
day þ60 ALC of 374 cells/mL (range, 28-2450 cells/mL) and
day þ90 ALC of 700 cells/mL (range, 80-2700 cells/mL). There
were no signiﬁcant differences in ALC at day þ30, þ60,
or þ90 between patients who eventually relapsed compared
with those who remained in remission (P ¼ .10, .40, and .80,
respectively). The median ALC was higher in the patients
who received aDLI (day þ120, 1118 cells/mL; day þ180, 1250
cells/mL) than in those who did not receive aDLI (day þ120,
304 cells/mL; day þ180, 678 cells/mL), but the difference was
not statistically signiﬁcant at either day þ120 (P ¼ .35) or
day þ180 (P ¼ .79).
Chimerism
All recipients demonstrated evidence of donor engraft-
ment before the ﬁrst scheduled aDLI. Donor chimerism at
dayþ90 ranged from 63% to 100% (median, 90%). Before aDLI
1, 2 patients exhibited donor chimerism of 99%-100%, which
remained stable after aDLI 1. Of the remaining 10 patients
who received aDLI 1, 3 had a>5% increase in donor chimerism
afteraDLI;whole-blood chimerism increased from92% to99%
in 1 patient and from75% to 94% in a second patient. In a third
patient, lymphoid chimerism increased from 61% to 73%,
whereas whole blood chimerism remained consistent, at 99%
before aDLI and 97% after aDLI. Six of the remaining 7 patients
exhibited a<10% change indonor chimerismwithout relapse.
The seventh patient experienced relapse, with a concurrent
drop inwhole-blood chimerism from77% to 6%. Three of the 6
patients who received aDLI 2 had >95% donor chimerism
before aDLI, which remained stable after aDLI 2. One patient
had an increase in whole-blood chimerism from 79% to 88%,
another patient demonstrated stable donor chimerism at
85%-87%, and 1 patient experienced a drop in donor chime-
rism from 66% to 37% in the setting of relapse.
Acute and Chronic GVHD
Three patients developed acute GVHD before the ﬁrst
scheduled aDLI and did not receive aDLI (Table 3). Two
patients developed acute GVHD after aDLI 1, 1 with index B
skin disease with onset at day þ161 after HSCT (day þ31 after
Figure 2. Representation of patient outcomes.
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onset at day þ186 after HSCT (day þ51 after aDLI 1). None of
the 6 patients who received both aDLI 1 and aDLI 2 developed
acute GVHD after the second infusion with >24 months of
follow-up.
Seventeen of the 18 patients were alive beyond day þ100,
and none developed chronic GVHD. One patient with
secondary AML developed distinct autoimmune phenomena
(uveitis, hypothyroidism, and vitiligo) at different time
points after HSCT with onset of self-limited uveitis after aDLI
1, precluding further infusions. Hypothyroidism and vitiligo
occurred beyond 1 year and were not associated with classic
chronic GVHD according to National Institutes of Health
criteria; this patient remains alive and in remission at
61 months after HSCT.
Infection
One early transplantation-related death occurred due to
sepsis at day þ53. Eight of the 13 patients at risk owing toTable 2
Engraftment results
Days from day 0 to
ANC >500 cells/mL
Days from day 0 to
platelets >20,000/mL
ALC on day
þ30, cells/mL
ALC on da
þ60, cells
Median 18 12 100 374
Range 0-27 0-118 0-1326 28-2450
SE 1.6 6.3 72.3 149.1cytomegalovirus (CMV) mismatch developed asymptomatic
CMV reactivation at median day þ36 (range, 17 to 48 days)
and were treated preemptively with ganciclovir. One patient,
who had received both aDLI infusions, developed progressive
multifocal leukoencephalopathy at approximately 11months
after HSCT. Of note, this patient suffered from psoriatic
arthritis and had used etanercept until 4 months before
HSCT.
Relapse
Eleven patients relapsed at a median of 191 days (range,
61 to 1000 days). Only 1 relapsed patient remained alive at
58 months of follow-up. After relapse, this patient received
standard unmanipulated DLI at 1.8  108 cells/kg, and
demonstrated a complete hematologic response and full
donor chimerism; the response was complicated by acute
GVHD of the oropharynx, skin, eyes, and liver. Among the 10
relapsed patients who died, 4 received 1 prophylactic aDLI
infusion, 3 received both prophylactic infusions, andy
/mL
ALC on day
þ90, cells/mL
ALC post- aDLI 1,
cells/mL
ALC post- aDLI 2,
cells/mL
Duration of
lymphopenia,
days
700 1118 1250 72
80-2700 100-4000 900-3300 19-252
163.3 318.2 366.7 14.6
Table 3
Patient outcomes
Patient Age, yr Disease status Donor/source ADLI 1 ADLI 2 Acute GVHD,
yes/no, timing
Chronic GVHD,
yes/no
Maximum
chimerism, %
Current status Cause of
death
1 63 ALL, CR1 Sibling/PBSCs No No Yes, day þ94 No 99 Expired, day þ157 Sepsis
2 63 AML, CR1 URD/PBSCs Yes No Yes, day þ161 No 96 Expired, day þ301 Disease
3 63 AML secondary, CR1 URD/PBSCs Yes No No No 100 Alive in CR at 47 mo d
4 54 ALL, CR2 Sibling/PBSCs Yes No No No 81 Expired, day þ515 Disease
5 59 ALL, CR2 URD/PBSCs Yes Yes No No 100 Expired, day þ891 Disease
6 61 MDS, <5% blasts URD/PBSCs Yes Yes No No 99 Relapse at 33 mo,
alive at 44 mo
d
7 59 AML, CR1 URD/PBSCs No No Yes, day þ126 No 99 Alive in CR at 44 mo d
8 64 AML, CR2 Sibling/PBSCs Yes Yes No No 99 Expired, day þ670 Disease
9 67 AML, CR1 URD/PBSCs Yes No No No 100 Expired, day þ533 Disease
10 60 AML, CR1 Sibling/PBSCs Yes No No No 100 Expired, day þ263 Disease
11 68 AML, CR2 URD/PBSCs Yes Yes No No 94 Expired, day 357 Disease
12 60 AML, CR1 Sibling/PBSCs No No No No 98 Expired, day þ201 Disease
13 57 AML, CR2 Sibling/PBSCs No No Yes, day þ50 No 100 Expired, day þ53 Sepsis
14 66 AML, CR1 from MDS URD/PBSCs Yes No Yes, day þ186 No 83 Alive in CR2 at 37 mo d
15 65 AML, CR1 Sibling/PBSCs No No No No 99 Expired, day þ191 Disease
16 57 AML, CR2 Sibling/PBSCs Yes Yes No No 99 Alive in CR at 34 mo d
17 59 AML, CR1 Sibling/PBSCs Yes Yes No No 100 Expired, day þ562 PML
18 60 AML, CR1 Sibling/PBSCs No No No No 92 Expired, day þ222 Disease
PML indicates progressive multifocal leukoencephalopathy; URD, unrelated donor.
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the 5 patients with documented GVHD relapsed, at 117 days
after GVHD onset. Correlation analysis showed a signiﬁcant
negative correlation between relapse and GVHD (Kendall
T ¼ -0.523; P ¼ .031).Figure 3. Kaplan-Meier estimates of overall and disease-free survival. (A)
Estimated overall survival at 2 years for all patients was 55%. (B) Estimated
relapse-free survival at 2 years for all patients was 49%.Survival
Seventeen of the 18 patients (94%) were alive at
day þ100; 1 patient died at day þ53 from multiorgan failure
related to sepsis. Five of the 18 patients (28%) remain alive at
a median follow-up of 58 months (range, 35 to 48 months).
Disease recurrence accounted for 10 of the 13 deaths (77%);
sepsis associated with GVHD, for 2 deaths (15%); and
progressive multifocal leukoencephalopathy, for 1 death
(8%). Of the 5 surviving patients, 1 patient had high-risk MDS
and relapsed 33 months after aDLI 1, and had received
a lower than planned dose of aDLI 2 owing to poor ex vivo
expansion. Four patients survive in remission; 2 of these
patients received both aDLI 1 and aDLI 2, 1 patient received
only aDLI 1, and 1 patient received no aDLI. Of the 5 surviving
patients, 4 received their peripheral blood stem cells from
unrelated donors, and 1 received them from a matched
sibling donor.
aDLI Functional Analysis
To better deﬁne cytotoxicity and function of ex vivo
stimulated cells before infusion in recipient cells, intracel-
lular cytokine production in CD4þ and CD8þ cells was
measured by ﬂow cytometry before and after exposure to
staphylococcal enterotoxin B (SEB) in a patient who had
received both aDLI 1 and 2 and was alive in CR. After SEB
exposure, the patient showed a marked apparent increase in
levels of IL-2, TNF, IFN-g, and the degranulation marker
CD107a within CD4þ and CD8þ cells (Figure 4).
To measure the potential for antigen-speciﬁc responses, 5
donor samples of the aDLI product were subjected to ELISpot
assays of IFN-g secretion before and after exposure to CMV
peptides. Two of the 5 evaluable donors mounted a speciﬁc
response to antigen, rising from 0 to >800 positive effector
cells/million MNCs. Of the 2 reactive donor samples, 1
recipient was at risk for CMV reactivation and in fact did
reactivate after HSCT (but before aDLI). Of the remaining 3
samples that did not mount a reaction to CMV peptides, 2
were at risk for reactivation, and 1 of these reactivated.
An ELISpot assay for IFN-g was performed on recipient
samples at days -30, þ60, þ90, þ120, þ170, and þ365. Seven
patients had at least 4 evaluable samples. Two of these
7 patients demonstrated no measurable increase in
Figure 4. Intracellular cytokine production in CD4þ and CD8þ cells was
measured by ﬂow cytometry before and after exposure to SEB in patient 16,
who is alive in CR after receiving 2 aDLI infusions. After SEB exposure, there
was a marked apparent increase in levels of IL-2, TNF, IFN-g, and the
degranulation marker CD107a within CD4þ and CD8þ cells.
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remaining 5 patients showed an increase after either aDLI 1
or aDLI 2, and 1 patient exhibited a decrease at day þ180 and
just before disease relapse. The seventh patient studied
demonstrated a delayed increase at day þ180. Of the 7
patients, 2 remained alive and in CR, 1 with a decreased
number of effector cells and the other with delayed increase
at dayþ180. Taken together, these planned correlative assays
do not appear to be robust biological correlates for outcome
in this cohort.
The percentage of regulatory T cells (Tregs) was also
evaluated in the expanded T cell product (as measured by
CD4þCD25þFoxP3þ events) and compared with pre-
expanded baseline. All 5 samples had <5% Tregs before
expansion. After Tcell expansion, 4 of the 5 samples had< 7%
Tregs. Of these 4 patients, none developed GVHD; 2 ulti-
mately died of disease, 1 died from progressive multifocal
leukoencephalopathy, and 1 was alive in CR at the time of
manuscript preparation. The ﬁfth sample tested contained
approximately 24% Tregs in the expanded product. This
patient received 2 infusions of aDLI and remains alive and
disease-free, with no GVHD.
DISCUSSION
In this study, we have demonstrated the safety and
feasibility of prophylactic aDLI administered after RIC HCST
using in vivo T cell depletion with alemtuzumab in adults
with high-risk hematologic malignancies. The use of aDLI is
based on the hypothesis that ex vivo costimulated Tcells may
provide a more potent GVL effect than conventional DLI by
maximizing T cell effector function [17]. We have previously
demonstrated that ex vivo costimulated aDLI is feasible and
safe after relapse in patients who underwent HLA-matched
allogeneic HSCT and induced high remission rates [11]. Thisis the ﬁrst study to investigate the use of prophylactic aDLI
before relapse.
In this study, we used alemtuzumab prophylaxis to
minimize the risk of early GVHD, an accelerated taper of
tacrolimus, and methotrexate, followed by aDLI to restore
GVL activity. Alemtuzumab, an anti-CD52 monoclonal anti-
body, has been used for in vivo T cell depletion to limit GVHD
after HSCT [18]; its use is associated with an increased risk
for relapse and decreased disease-free survival, however
[3,19]. In our study, alemtuzumab proved to be effective in
minimizing GVHD, with minimal early (5 of 18) and no late
acute GVHD or chronic GVHD. The reported incidence of
GVHD after conventional DLI is 40%-60% [8]. The low inci-
dence of GVHD seen after aDLI suggests low toxicity related
to aDLI and may be related to alemtuzumab, or simply to the
small numbers of patients treated on this protocol. With the
exception of 1 sample, we did not observe a robust expansion
in Tregs, although the number of Tregs that would decrease
GVHD (and possibly GVL) is not known. The role of Tregs in
the GVL effect has not beenwell deﬁned, although they have
been associatedwith both preserved GVL activity and disease
progression [20-22]. These ﬁndings suggest that the use of an
alemtuzumab-based conditioning regimen allowed rapid
taper of immune suppression and prophylactic administra-
tion of aDLI without inducing excessive GVHD.
The schedule for prophylactic aDLI was set at days þ120
and þ180, to allow time to discontinue immunosuppression
and ensure that patients would not develop GVHD. Data
suggest that toxicity from GVHD may be more tolerable if
isolated from the cytokine phase and other toxicities asso-
ciated with HSCT (related to, eg, conditioning regimen, tissue
damage, infections) [23]. Attempts to enhance GVL early after
HSCT by limiting GVHD prophylaxis or administering addi-
tional donor T cells have resulted in excessive toxicity
without improved relapse rates [24-26]. After a suitable
delay, DLI can be administered post-HSCT with acceptable
toxicity and provides potent GVL activity both in animal
models [27-29] and in clinical practice [30-32]. On the other
hand, the biological impact of the later DLI is not known and
may come at the cost of more robust homeostatic prolifera-
tion of infused cells, and it may be reasonable to maximize
GVL induction earlier. In future studies, a more rapid tacro-
limus taper may permit even earlier prophylactic DLI to
prevent relapse, and better methods for tracking in vivo
survival and proliferation of activated donor cells may better
deﬁne the GVL biology of these cells.
There is evidence that mixed chimerism after HSCT may
predict subsequent relapse, and that prophylactic DLI and
DLI can result in conversion to complete donor chimerism
[31,33]. Of note, in the present study, only 3 of 10 patients
with <95% donor chimerism before aDLI 1 achieved at least
a 5% increase in donor chimerism after aDLI 1. Whether the
lack of conversion to donor chimerism is related to poor
survival of the ex vivo activated cells or simply to the high-
risk population in this study is unknown.
This pilot study was not designed or powered to identify
a true GVL effect of aDLI. All patients were at high risk for
relapse, and 11 of the 18 patients ultimately sustained
disease relapse. To date, 4 patients are alive and in remission.
Given the high rate of relapse, the ﬁnding that aDLI did not
result in complete conversion to donor chimerism in all
patients, and the limited GVHD, the possibility that the
ex vivo costimulated and expanded activated T cells could
result in less GVL than unstimulated donor T cells must be
considered. Immunophenotyping showed no evidence of
A.J. Kumar et al. / Biol Blood Marrow Transplant 19 (2013) 1094e11011100T cell exhaustion; for example, there was uniformly high
expression of CD28 and CD62L. In previous studies in which
cells stimulated in a similar fashion were gene-transduced
and more extensive phenotyping was performed, we found
a >1000-fold in vivo expansion and effector memory
phenotype at 2 months after infusion, and a central memory
phenotype 6months after infusion [34,35]. In clinical trials in
HIV, we observed that cells stimulated in the same manner
can persist for a decade [36].
Another consideration is that the delay of initial aDLI to
beyond day þ120 in the present study attenuated the
potential GVL effect compared with aDLI given early after
conditioning. Previous studies in patients with lymphoma and
myeloma treated with autologous activated T cell infusion
have demonstrated high rates of autologous GVHD and
lymphocytosis after infusion [37-39]. Randomized trials have
shown that autologous activated T cell infusions given early
(dayþ2 to dayþ12) are more effective than delayed infusions
in adults [40] and children [41]. Consistent with this possi-
bility is that the patients in the preseent study did not develop
lymphocytosis, in contrast to the aforementioned infusions of
activated autologous T cells given early after conditioning.
Our study shows that the use of prophylactic CD3/CD28
costimulated DLI is safe, feasible, and is not associated with
signiﬁcant incidence of GVHD in patients with high-risk
hematologic malignancies after RIC allogeneic HSCT.
Disease progression remains a signiﬁcant cause of mortality.
The high relapse rates observed in our cohort suggest that
alternative strategies of minimizing GVHDwhile maximizing
GVL are still needed.ACKNOWLEDGMENTS
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